Document is current

Article History

Received: 26 August 2024

Accepted: 9 October 2024

First Online: 23 October 2024

Declarations

:

: The investigators agreed to conduct the human study according to the principles of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guideline E6: Good Clinical Practice. The investigators performed all aspects of this study in accordance with the ethical principles that have their origin in the Declaration of Helsinki, the study protocol, and all national, state, and local laws or regulations. The original study protocol and protocol amendments were approved by appropriate institutional review boards and ethics committees at the following sites: Advarra (Columbia, MD, USA), The Alfred Hospital (Melbourne, Australia), Medical Research Ethics Committee of the Foundation BEBO (Assen, Netherlands), Skipton House (London, UK). For animal studies, all experimental procedures were conducted according to the approved protocols from the relevant institutions: 4-week GLP study, Covance Laboratories, Inc #8372868; DRF study, Covance Laboratories, Inc #8372866; non-GLP interval study, Charles River Laboratories, Inc. # 2946-001. All procedures complied with the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the Office of Laboratory Animal Welfare.

: Not applicable.

: H.L., A.S., A.M., Br.B., T.N., Ba.B., An.R., and Ar.R. are employees of Alector, LLC and may have an equity interest in Alector, Inc. D.M., H.R., I.T., M.W., T.S., and R.P. were employees of Alector at the time of manuscript conception and may have an equity interest in Alector, Inc.